Overview

Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis

Status:
Completed
Trial end date:
2016-10-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).
Phase:
Phase 3
Details
Lead Sponsor:
Radius Health, Inc.
Treatments:
Alendronate